Le Lézard
Classified in: Ebola virus, Health, Covid-19 virus
Subject: PER

Crossroads Treatment Centers Adds Dr. Jerome Adams to Board


Respected physician and former U.S. Surgeon General to help guide treatment initiatives

GREENVILLE, S.C., July 19, 2023 /PRNewswire/ -- Crossroads Treatment Centers (Crossroads) has added Dr. Jerome Adams to its Board of Directors.

Crossroads Treatment Centers (Crossroads) has added Dr. Jerome Adams to its Board of Directors.

Dr. Adams was the 20th U.S. Surgeon General and a prior member of the White House Coronavirus Task Force.  He is currently a Distinguished Professor in the Departments of Pharmacy Practice and Public Health at Purdue University, where he is a Presidential Fellow and the Executive Director of the University's Health Equity Initiatives.

As U.S. Surgeon General, Dr. Adams was the operational head of the 6,000-person U.S. Public Health Service Commissioned Corps.

Dr. Adams is a licensed anesthesiologist with a master's degree in public health. Prior to becoming Surgeon General, he led the Indiana Department of Health. As Indiana State Health Commissioner, he managed a $350 million budget, directed more than 1,000 employees, and led Indiana's response to Ebola, Zika, and the HIV crisis.

Dr. Adams also worked with the Indiana governor and state legislature to legalize syringe service programs in Indiana.  He has partnered with and assisted multiple organizations as they navigate the opioid epidemic, increasing rates of chronic disease, the impacts of rising suicide rates in the U.S., and how businesses can become better stewards in promoting community health.

"Dr. Adams has been a leading, authoritative voice in the medical community, working to address America's most pressing health challenges," says Dr. Rupert McCormac IV, Founder and CEO of Crossroads. "He particularly understands the challenges involved with addressing the health equity gaps in access to quality care and will be invaluable to Crossroads as we continue to help to reduce the barriers to treatment for those with substance use disorder."

About Crossroads Treatment Centers

Since 2005, Crossroads has been at the forefront of treating patients with opioid use disorder. Currently operating more than 110 clinics across 9 states (GA, KY, NJ, NC, PA, SC, TN, TX, and VA), we are a family of doctors, nurse practitioners, counselors, and professionals dedicated to providing the most accessible and highest quality treatment options to combat the growing opioid epidemic.

Contact:         

Crystal Fuller Morley, Vice President of Marketing & Communications


[email protected]


(615) 294-5768

SOURCE Crossroads Treatment Centers


These press releases may also interest you

at 12:36
Kedrion Biopharma Inc., an international biopharmaceutical company specializing in the research and development, production, and commercialization of plasma-derived therapeutic products used in treating rare and serious diseases, announced today that...

at 12:28
PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, today announced it was selected by X4 Pharmaceuticals, Inc. for the distribution of XOLREMDItm (mavorixafor), recently approved by the U.S....

at 12:20
Soleo Health, a national provider of complex specialty pharmacy services, announced today the opening of its latest pharmacy and ambulatory infusion center (AIC) in Ridgeland, Mississippi. Soleo Health Jackson offers a broad range of specialty...

at 12:08
Prices have gone up?and stayed up?since the pandemic, but Eyemart Express has bucked this consumer pricing trend by keeping its prescription eyewear affordable. Since its founding in 1990, the national optical retailer has remained committed to...

at 12:05
Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic...

at 12:05
Pharmaceutical Strategies Group ("PSG"), an EPIC company, released its annual Trends in Specialty Drug Benefits Report, co-sponsored by Genentech, a member of the Roche Group, detailing the complexities of specialty drug access and affordability. The...



News published on and distributed by: